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Background and rationale 
Prostate cancer is the most frequent cancer in men, placing a high burden on patients and healthcare 
systems. With an age-standardized incidence of 115.7/100,000 person-years, prostate cancer is 
currently estimated to affect over 43,000 patients in Switzerland 1. Prostate cancer is characterized by 
a relatively slow disease progression, especially when detected and treated in early, localized stages. 
This manifests in a relatively high 5-year survival of 88.6% after diagnosis, while the mortality rate of 
22.0/100,000 person-years is still high compared to other cancer types 1. Prostate cancer and its 
progression typically are androgen-dependent and respond well to treatments that reduce the 
production of androgens including testosterone. Androgen deprivation therapy (ADT) is the standard 
of care for men with metastatic, hormone-sensitive prostate cancer (mHSPC), either by means of 
surgical castration (orchiectomy) or medical castration 2. These treatments constitute the mainstay of 
therapy for prostate cancer patients in high-risk localized as well as advanced (i.e., locally progressive 
or metastatic) disease stages. In recent years, substantial advances have been made in the treatment 
of prostate cancer, significantly improving the prognosis of patients with advanced disease. 
A subject of high current scientific interest is the management of patients with newly diagnosed 
mHSPC 3–5. Patients are typically diagnosed with mHSPC either as their first diagnosis of prostate 
cancer, or in the context of progression from localized to metastatic disease. Patients are defined as 
having "hormone-sensitive" disease if they have either not previously received ADT or have 
demonstrated ongoing sensitivity to ADT. Several different treatments are now available that have 
shown benefits in mHSPC patients in combination with ADT. These treatments include chemotherapy 
with docetaxel, novel hormonal treatments (i.e., second-generation anti-androgens) such as 
abiraterone, enzalutamide and apalutamide, as well as radiotherapy. Both docetaxel and abiraterone 
demonstrated significant effects in prolonging overall survival 6–13. Enzalutamide and apalutamide 
showed promising results on overall survival in early analyses 14–16. These effects may, however, 
depend on the volume and risk category of the disease, as well as on whether mHSPC was diagnosed 
de novo (i.e., as the first diagnosis) or after prior local therapy (i.e., local treatment of the primary 
tumor). Additionally, external beam radiotherapy to the prostate has been shown to have survival 
benefits in the subgroup of prostate cancer patients with low disease volume, but not in the overall 
mHSPC population 17,18. The optimal treatment for men with newly diagnosed mHSPC is thus currently 
unclear and additionally depends on clinical factors and patient preferences. 
Only treatment with abiraterone (limited to high risk mHSPC) has received marketing approval for 
mHSPC by swissmedic, and is regularly reimbursed by the Swiss statutory health insurance 19,20. 
Docetaxel is commonly used off-label in this indication. Docetaxel is available as a generic drug in 
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Switzerland 19, while a current legal dispute over the patent on abiraterone in the United States may 
open the market for generic versions of this drug before formal patent expiration 21. According to 
Swiss experts, local radiotherapy primarily performed in men with newly diagnosed mHSPC with low 
disease volume or low risk and a good overall health state. Currently, radiotherapy is rather seen as a 
supplement to systemic therapies in Switzerland. This is also reflected in current clinical practice 
guidelines 22. 
 
Aim of this HTA 
The aim of the economic part of this Health Technology Assessment (HTA) is to assess and evaluate 
the cost-effectiveness and budget impact of the different available systemic first-line treatments for 
adult men with newly diagnosed mHSPC.  
 
PICO 
This chapter describes the PICOs (Population, Intervention, Comparator, Outcomes) of the economical 
part but also the clinical parameters used as input into the health economic analysis. 
Population 
The primary target population of this HTA are adult men with mHSPC that have not previously 
undergone systemic therapy. Study participants will be considered eligible if they have not previously 
received ADT, have received ADT but more than 12 months prior to enrollment for a total duration of 
less than 24 months, or have received ADT but for less than 6 months prior to enrollment and without 
clinical, biochemical or radiographical indication of disease progression. We will exclude patients with 
non-metastatic (M0) prostate cancer, as well as patients that have received chemotherapy or newer-
generation hormonal therapy prior to enrollment. 
In case we identify studies from which only a subpopulation of participants fulfills the eligibility 
criteria, we will include the study and use corresponding subgroup data in our analysis if the main 
outcomes necessary for the health economic analysis are available. If no stratified data are available, 
we will use data from the overall study population or a subpopulation which we judge to be most 
applicable, if at least 80% of participants are eligible or if there is sufficient evidence to assume an 
absence of effect modification across the corresponding strata. Else, we will exclude the study from 
the primary analysis and conduct sensitivity analyses including data from these studies. 
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We define metastatic cancer as the presence of one or more distant metastases irrespective of the 
extension of the primary tumor and lymphatic spread (i.e., M1 stage with any T and N stage according 
to the TNM classification). The term "hormone-sensitive" will be considered synonymous to the terms 
"castration-sensitive", "hormone-naïve" and "castration-naïve" prostate cancer. This includes clinical 
scenarios in which patients have either not previously received ADT or have demonstrated ongoing 
sensitivity to ADT 3. Studies including more than 10% of patients with rare forms of prostate cancer, 
such as aggressive variant prostate cancer (i.e., with neuroendocrine differentiation or small cell 
features) are excluded. Patients with non-metastatic (M0) prostate cancer are excluded, but may be 
considered in secondary analyses or if data availability dictates so. 
Intervention 
The following interventions will be considered eligible: 
• ADT + docetaxel, intravenous chemotherapy (in combination with prednisone) followed by 
ADT alone 
• ADT + abiraterone (in combination with prednisone), daily oral medication 
• ADT + enzalutamide, daily oral medication 
• ADT + apalutamide, daily oral medication  
• ADT + radiotherapy, external beam radiation therapy to the prostate followed by ADT alone 
(for a potential subgroup analysis of de novo low risk patients) 
Any concurrent or protocolized immediate sequential combination of the aforementioned treatments 
will also be included. 
Excluded interventions are: 
• Bone agents (such as zoledronic acid) 
• COX-2 inhibitors (such as celecoxib) 
Comparator 
The aforementioned experimental interventions will be compared between each other and against 
the following comparator intervention: 
• ADT alone or in combination with first-generation non-steroidal anti-androgens. 
ADT may involve treatment with gonadotropin-releasing hormone agonists or antagonists, or bilateral 
orchidectomy, alone or in combination with first-generation non-steroidal anti-androgens (such as 
bicalutamide, flutamide or nilutamide). 
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Clinical parameters 
The following outcome parameters of the clinical systematic review are considered as inputs for the 
health economic analysis: 
• Overall survival (OS) 
• Progression-free survival (PFS) (expressed by one of the following outcomes, whichever is 
judged to most closely reflect a meaningful clinical progression in the following order of 
priority): 
- Clinical PFS (cPFS) defined as the time from randomization to first clinical or radiographic 
progression, or death. 
- Radiographic PFS (rPFS) defined as the time from randomization to first radiographic 
progression, or death. 
- Failure-free survival (FFS): Defined as the time from randomization to first clinical, 
radiographic or biochemical (prostate-specific antigen, PSA) progression, or death. 
• Biochemical (PSA) PFS (bPFS): Defined as the time from randomization to first biochemical 
(PSA) progression, or death. Overall health-related quality of life (QoL) (e.g. measured by the 
EQ-5D instrument) 
• Grade 3-4 adverse events (AEs)  
 
Health Economic outcomes 
• Relevant resource use parameters (including among others: doses of medications, frequency 
and type of drug administration, frequency and extent of physician visits, frequency and type 
of imaging, resource use due to AEs) 
• Direct costs related to resource use utilization (drug cost for first-line and further-line 
concomitant medication, administration costs, physician visit costs, imaging costs, AE costs) 
• Quality-adjusted life years (QALY) gained, life-years (LY) gained 
• Incremental cost-effectiveness ratio (ICER; costs per QALY or LY gained) 
• Budget impact estimates (estimated number of cases per year and related costs) 
 
Health economic systematic literature review 
A systematic review of the current health economic literature is currently being undertaken. Literature 
on the cost-effectiveness of abiraterone, enzalutamide, apalutamide, docetaxel, and radiotherapy in 
patients with mHSPC is identified. The identified economic studies will be critically assessed according 
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to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist 23. Plausibility 
of the results and the transferability of international results to Switzerland will be considered.  
Main results will be summarized in tabular and/or graphical formats and synthesized narratively. 
 
Cost-effectiveness analysis 
Model structure and development 
A de novo cost-effectiveness analysis will be conducted for Switzerland including all treatments listed 
in the PICO, with the exception of local radiotherapy. An additional analysis of the subgroup of de 
novo low-risk patients comparing ADT monotherapy to ADT+radiotherapy might be envisaged. A 
three-health state Markov (M) model with the states of progression-free survival (PFS), progressive 
disease (PD) and death (D) will be developed. We will choose a model cycle length of 1 month applying 
half-cycle correction. We further assume that a very large percentage of the patients (90-95%) 
receives second and further lines of treatment within a 15-year time horizon. Due to the complexity 
and diversity of the possible follow-up treatments, a possible lack of information, and their 
dependence on first-line treatment, we may combine post-progression treatments in one 
“progressive disease” health state. 
The original Kaplan-Meier (KM) OS and PFS curves from relevant studies (consistent with the clinical 
part of this HTA) will be digitalized (Software DigitizeIt). For this purpose, individual patient data (IPD) 
and Kaplan-Meier estimates will be re-created following the approach of Guyot et al. 24. The 
proportional hazard (PH) assumption will be verified based on the Schoenfeld test and/or based on 
visual inspection 25. In case it is not substantially violated, frailty models or mixed effects Cox models 
will be used to perform a meta-analysis of the various ADT time-to-event curves. Survival curves of 
the intervention arms will be obtained by applying hazard ratios to the ADT baseline hazard. We intend 
to perform long-term data extrapolation by fitting different parametric distributions to the pooled 
ADT data. Survival curves with the best fit, based on the Akaike and Bayesian information criterion 
(AIC and BIC) as well as based on clinical plausibility of long-term model extrapolations will be selected 
for the time periods after the study have ended, and combined with general population mortality in 
Switzerland. In case the PH assumption is substantially violated, other methods like e.g. flexible 
parametric models or piecewise exponential models will be explored 26,27.  
If intermediate results generated during the research process lead to modifications of the described 
approach, this will be transparently reported. 
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Perspectives 
The cost-effectiveness analysis will be performed from a 'KVG perspective' (considering the direct 
medical costs of all health care services covered by the Swiss statutory health insurance, irrespective 
of the actual payer).  
Time horizon 
The time horizon for the cost-effectiveness analysis needs to be long enough to capture the clinical 
and economic differences arising from the different treatment options. All treatments of interest are 
relatively new, and the longest-follow period available from an original study is 9 years. Hence, long-
term extrapolation underlies very substantial uncertainty. As a compromise, we plan a time horizon 
of 15 years in a base case analysis. A lifelong time horizon (30 years), conceptually the most 
appropriate, may be envisaged in a scenario analysis implying a need for a longer and more uncertain 
extrapolation.  
Discounting 
Costs and utilities will be discounted at an annual rate of 3.0%.  
 
Uncertainty 
In order to investigate parameter and structural uncertainty, we will perform one-way and 
probabilistic sensitivity analyses, and several scenario analyses. 
 
For the probabilistic sensitivity analyses, we plan to assign gamma distributions to unit cost 
parameters, beta distributions to utilities and probabilities. Parameter estimates of the OS and PFS 
curves will be assigned normal distributions, and hazard ratios log-normal distributions. Distribution 
parameters considering available standard errors will be used for the probabilistic sensitivity analyses 
with 10,000 simulation runs. Where standard error estimates or 95% confidence intervals (CIs) are not 
available, we will assume standard errors to be 20% of the base case parameter values (10% for 
utilities). For the univariate sensitivity analyses, available 95% CIs will be used as the maximum and 
minimum boundaries. Otherwise, we plan to vary the base case parameters by ±30%. 
 
The selection of scenario analyses to be performed will depend on intermediate results. 
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Budget Impact Analyses 
Budget impact analyses will be performed to compare the overall costs of ADP therapy alone with 
scenarios including ADT + docetaxel, ADT + abiraterone, ADT + enzalutamide, ADT + apalutamide in 
Switzerland assuming different market shares.  
The analysis will consist of two main steps: first, the annual number of patients with mHSPC will be 
estimated; second, based on the annual number of cases and the costs estimated in the cost-
effectiveness analysis, the total annual costs will be estimated. 
Since patients are typically diagnosed with mHSPC either as their first diagnosis of prostate cancer or 
in the context of progression from localized to metastatic disease, the estimation of the annual 
number of potentially eligible cases will consist in a combination of incident and prevalent prostate 
cancer cases. 
Data from NICER will provide an estimate of the yearly total number of new prostate cancer cases 
diagnosed (incident cases) as well as the total number of prostate cancer patients (prevalent cases) in 
Switzerland.  
• Incident cases: it will be assumed that all newly diagnosed prostate cancers are hormone 
sensitive. To estimate which percentage of these patients may have a metastatic condition, 
we will apply national or published estimations. For example, in a report recently published 
by the German Institute for Quality and Efficiency in Health Care (IQWiG), the percentage of 
metastases among newly diagnosed prostate cancers ranged from 5.57% to 7% 28. A 
systematic review and meta-analysis investigating the diagnostic performance of magnetic 
resonance imaging for the detection of bone metastasis in prostate cancer reported that the 
percentage of metastasis in four studies including newly diagnosed prostate cancer patients 
only ranged from 6.8% to 25.0% 29. In the base case scenario we may assume that 10% of the 
newly diagnosed patients have mHSPC, whereas in the sensitivity analysis we will vary the 
assumed percentage (e.g. from 5% to 20%). 
• Prevalent cases: published literature will be screened to investigate which percentage of the 
already known prostate cancer patients progress to mHPSC. 
In the second step the estimated number of cases will be combined with undiscounted costs derived 
from the cost-effectiveness model.  The budget impact will be estimated over a period of several years 
(e.g. from 2020 to 2025). The cost calculations will take into consideration initial treatment costs (i.e. 
costs in the first treatment year) as well as follow-up costs (costs in the following years). This means 
that every year we will sum the costs of newly diagnosed and treated mHSPC patients (first-year 
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treatment) with follow-up treatments of already known mHSPC cases (second/third/etc. treatment 
year). 
The total costs will be calculated assuming that all patients receive the same therapy as well as 
assuming different market shares (e.g. 20% ADT + docetaxel, 40% ADT + abiraterone, 40% 
ADT + enzalutamide). 
Several sensitivity and scenarios analyses will be performed to investigate how higher/lower 
prevalence and costs of mHSPC may influence the total costs. 
 
Sources for resource use and costs 
We plan to obtain information required for the economic analysis through 
• The results of the clinical part of the assessment 
• The results of the systematic health economic literature review 
• Input from Swiss clinical experts in mHSPC 
• The Swiss specialty list for drug prices (www.spezialitätenliste.ch) 
• Swiss Hospital Statistics 2018: patients with prostate cancer will be identified through relevant 
treatments (e.g. CHOP codes), diagnostic codes (i.e. ICD-10 codes), and hospitalization codes 
(i.e., SwissDRG codes)  
• Diagnosis Related Group case weights (SwissDRG online definition handbook 8.0 or a newer 
available version) for inpatient hospital costs 
• Swiss tariff framework for ambulatory and outpatient care (TARMED online Browser Version 
1.09 or newer)  
• Swiss BAG “Analysenliste” for laboratory costs 
• Additional targeted searches, complemented with hand-searches of the grey literature and 
the world wide web (non-systematic) in order to identify manuscripts for event rates, health 
resource use and costs that were not available from the above-mentioned sources 
 
Further sources may be identified and added at a later point in time. 
 
Funding 
This project is funded by the Swiss Medical Board. 
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